Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer (Q28207208)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: February 2003)

Language	Label	Description	Also known as
English	Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer	scientific article (publication date: February 2003)

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

author name string

C Dittrich

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

L Paz-Ares

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

F Caponigro

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

M Salzberg

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

T Gamucci

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

X Paoletti

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

C Hermans

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

D Lacombe

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

P Fumoleau

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

European Organization for Research and Treatment of Cancer--Early Clinical Studies Group/New Drug Development Programme (EORTC-ECSG/NDDP)

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

language of work or name

0 references

publication date

1 February 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

39

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

330-334

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined inhibition of topoisomerases I and II - is this a worthwhile/feasible strategy?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900559-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(02)00559-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565985%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28207208&oldid=1412736317"